Mexico Pharmaceuticals & Healthcare Q4 2019
Mexico’s new public drug procurement system will create challenges for pharmaceutical operators across the supplychain, requiring business models to adapt to new drug distribution schemes and pricing pressure. The separation of drugdistribution from the direct purchase of medicines, which is aimed at reducing drug distribution costs and generating overallsavings, will increase operational risks in the near term. While the recent announcement of additional public funds to purchasemedicines will create opportunities for pharmaceutical companies in the near term, we continue to forecast decelerating growth inpharmaceutical spending over the coming years as the incumbent government looks to contain healthcare spending.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook